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Risk-stratification and treatment intensification according to minimal residual disease 
(MRD) analysis has improved outcomes of patients with acute lymphoblastic 
leukemia (ALL).1,2 However, a significant proportion of patients with T-cell ALL (T-
ALL) still experience early relapse or refractory disease. Robust prognostic markers 
able to identify high-risk patients at diagnosis have proved challenging, and risk-
adapted management for T-ALL remains an unmet need. The work presented here 
shows that the molecular marker, absence of biallelic deletion at the TRG locus, does 
not have a poor prognostic impact on the outcome of pediatric and adolescent patients 
with T-ALL treated on the risk-directed protocol of the MRC UKALL2003 trial.  
 
Early T-cell Precursor (ETP) T-ALL identified by immunophenotyping was 
previously reported to confer a poor prognosis in pediatric, adolescent and adult 
patients.3,4 However, immunophenotyping was found to underestimate the number of 
patients with an ETP gene-expression signature,5 and inter-laboratory diagnosis for 
this immunophenotype is not standardized. Moreover, gene-expression profiling is not 
widely utilized for clinical use. Therefore, an alternative molecular method based on 
the V-J recombination status of the T-cell receptor gamma (TRG) gene has been 
described.6 Given that TRG recombination occurs early during T-cell development,7 
cells that have not undergone biallelic deletion at the TRG locus have been termed 
‘ABD’ (Absence of Biallelic Deletion), with the majority of such ABD T-ALL cases 
having an ETP-ALL gene-expression signature.6 Consistent with the original reports 
of ETP-ALL,3 ABD was reported to be associated with inferior survival,6 although the 
patients studied were not treated on MRD risk-directed protocols. Thus we 
investigated whether ABD status adds further prognostic information for pediatric and 
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adolescent patients with T-ALL treated on the MRC UKALL2003 trial that used 
MRD risk to direct treatment intensity.1,8  
 
Whole genome amplified (WGA) DNA was available from diagnostic samples of 152 
of 393 (39%) T-ALL patients treated on this trial.9 Full details of the patient cohort, 
trial protocols, methods and statistical analyses are described in the Supplementary 
Information. The trial is registered at http://www.controlled-trials.com under ISRCTN 
number 07355119. Ethical approval for the trial was obtained previously from the 
Scottish Multi-Centre Research Ethics Committee on 25/02/2003, ref: 02/10/052, and 
samples were collected with informed consent according to the Declaration of 
Helsinki.  
 
Baseline characteristics and survival outcomes of these 152 patients were not 
significantly different from the 241 patients not included in the study (Tables S1-2, 
Figure S1). 
 
The TRG quantitative polymerase chain reaction (qPCR) assay determined fold 
change using the comparative ∆∆CT method with ANLN as the reference gene 
(TRG:ANLN), as previously described.6 There was good agreement between results 
from WGA material and their corresponding non-WGA sample where available 
(r2=0.92) (Figure S2A-B). Patients were assigned to the ABD group if the 
TRG:ANLN fold change was ≥0.5 and the diagnostic blast count ≥50% (to exclude 
lack of deletion due to contamination with non-leukemic cells), non-ABD if ≤0.25, 
and indeterminate if between these values (Figure 1A). Indeterminate results were 
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confirmed using COA1 as an alternative reference gene (Figure S2C). TRG locus 
deletions were also determined using data from Illumina CytoSNP-850K arrays.9  
 
By qPCR, 23 of 152 samples (15%) were classified as ABD, 110 (72%) as non-ABD, 
and 19 (13%) were indeterminate (16 with fold change 0.26-0.49; 3 with fold change 
>0.5 but blast count <50%) (Figure 1A). Baseline characteristics and survival of the 
19 patients with indeterminate status were similar to the other 133 patients (Tables 
S3-4, Figure S3). Baseline characteristics of the 133 patients according to ABD status 
are outlined in Table 1. Of these, 118 also had SNP array results at the TRG locus that 
were concordant with the qPCR findings (Figure 1 B-C), including 22 ABD patients; 
array data was uninterpretable or not available for the remaining 15 cases.  
 
However, there was no statistically significant difference in overall survival (OS) 
between the ABD and non-ABD groups (5-year OS, 87% vs 90% respectively; hazard 
ratio (HR) 1.67, 95% confidence intervals 0.54–5.17; P=0.37) (Figure 2A; Table S5). 
There was also no significant difference in the relapse-free survival (RFS) (82% vs 
89%; HR 1.58, 0.52–4.86; P=0.42) (Figure 2B; Table S5). Although there was a trend 
towards an inferior event-free survival (EFS) in the ABD group, this did not reach 
statistical significance (78% vs 85%; HR 2.12, 0.88–5.12; P=0.09) (Figure 2C; Table 
S5), and was impacted by 7 non-relapse events in the ABD group (1 infection-related 
death at induction, 4 deaths from causes other than ALL and 2 second malignancies). 
 
We have previously reported that patients treated on this trial with T-ALL and 
NOTCH1/FBXW7 double-mutant status had excellent OS (100%).10 However, the 
comparable survival of the ABD and non-ABD groups in our cohort could not be 
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explained by this molecular subtype, since only 2 of the 23 ABD patients (9%) had 
NOTCH1/FBXW7 double-mutant status.  
 
There was, however, a significant association between MRD levels and ABD status. 
Only 9% of the ABD patients were MRD-negative at day 29 compared with 35% of 
the non-ABD patients (P=0.01, Fisher’s exact test). Also, patients with ABD status 
and MRD results had higher median MRD levels compared with those with non-ABD 
status (2.519% vs 0.0173% positive cells; P=0.03) (Figure 2D), suggesting that ABD 
status may highlight a high-risk group that is already identified by high MRD levels.  
 
Moreover, more than 3 times as many ABD patients had an MRD indeterminate status 
compared to the non-ABD group (57% vs 16%; P<0.001, Mantel-Haenszel test) 
(Table 1). This was mainly due to the fact that a higher proportion of ABD patients 
lacked MRD targets at diagnosis than the non-ABD patients (38% vs 1% respectively; 
P<0.001, Fisher’s exact test). MRD was evaluated by real-time quantitative PCR 
analysis of the T-cell receptor gene rearrangement, and failure to detect a gene 
rearrangement target as an MRD marker in the ABD group is consistent with the same 
underlying biology as that of the ABD status, where developmental arrest occurs prior 
to VJ recombination. To address whether ABD status might be a useful alternative 
prognostic marker in this MRD indeterminate group, we analyzed outcome in this 
subgroup of patients. Our results show that in the MRD indeterminate cases who were 
eligible for RFS analysis, only 3 of 18 non-ABD (17%) and 1 of 12 ABD (8.3%) 
relapsed. Notably, MRD indeterminate status itself directed treatment intensity as 
these patients were not eligible on the trial for randomization to reduction of 
chemotherapy intensity. Thus, numbers are too small to make firm conclusions on the 
 6
additional prognostic significance of ABD in this subgroup, which would need to be 
addressed in a larger prospective trial. 
 
Our data is in marked contrast to the results from another study where the ABD 
subgroup, identified using the same TRG qPCR assay, was associated with a dismal 
outcome (5-year OS: 25% vs 72% in the ABD and non-ABD groups respectively).6 
However, these patients were not treated using MRD-directed therapy, suggesting that 
differences in treatment protocols may impact on prognosis of this subgroup. Within 
the ABD group of our cohort, 11 patients (48%) received the more intensive 
chemotherapy arm, Regimen C, including all the 8 MRD-positive patients, although 
none of the ABD patients proceeded to an allogeneic stem cell transplant in first 
remission. Notably, there was no statistical difference in the RFS of ABD and non-
ABD patients treated on Regimen C (P=0.21) (Figure S6A, Table S6). The RFS for 
ABD patients treated on Regimens A or B was 100%, although it should be noted that 
none of them were MRD-positive (Figure S6B, Table S6). There was a trend towards 
an increased risk of relapse in MRD-positive ABD patients when compared to MRD-
positive non-ABD patients (HR 3.22, 0.83–12.52; P=0.07) (Figure S6C), which might 
relate to higher median MRD levels.11  
 
The comparable survival of the ABD and non-ABD groups treated on the 
UKALL2003 trial is consistent with the outcome reported for patients on this trial 
according to their ETP status by immunophenotyping12. Moreover, the comparable 
survival between these two groups is also consistent with the outcome reported for 
ETP and non-ETP patients from other pediatric MRD risk-directed studies.13,14 In 
addition to this, our findings are similar to those recently reported for ABD status in 
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adult T-ALL patients treated using response-based risk stratification and therapy 
intensification, including allogeneic stem cell transplantation.15  
 
In conclusion, our data indicate that in pediatric/adolescent T-ALL, ABD status does 
not add further prognostic information nor justify treatment escalation beyond what 
can already be inferred by MRD analysis using a risk-adapted protocol. 
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Table 1: Baseline characteristics, treatment allocation, response and 
molecular characterization of the ABD and non-ABD groups. 
 
Non-ABD ABD 
P 
N=110 N=23 
Baseline characteristics     
Sex, N (%)    
 Male 88 ( 80.0) 16 ( 69.6) 0.27 
 Female 22 ( 20.0) 7 ( 30.4)  
WBC count (x10
9
 per L), N (%)    
 <50 24 ( 21.8) 15 ( 65.2) <0.001 
 ≥50 86 ( 78.2) 8 ( 34.8)  
Age, N (%)    
 <10 years 
64 ( 58.2) 8 ( 34.8) 
0.041 
 ≥10 years 46 ( 41.8) 15 ( 65.2)  
NCI risk group, N (%)    
 Standard 10 (  9.1) 4 ( 17.4) 0.26
*
 
 High 100 ( 90.9) 19 ( 82.6)  
CNS disease at diagnosis, N (%)    
 No 102 ( 92.7) 23 (100.0) 0.35
*
 
 Yes 8 (  7.3) 0  
Treatment Allocation and Response     
Final treatment given, N (%)    
 A 8 (  7.3) 3 ( 13.0) 0.12
*
 
 B 67 ( 60.9) 9 ( 39.1)  
 C 35 ( 31.8) 11 ( 47.8)  
Slow early Response, N (%)    
 No 74 ( 67.3) 11 ( 47.8) 0.14
§
 
 Yes 25 ( 22.7) 7 ( 30.4)  
 Unknown
#
 11 ( 10.0) 5 ( 21.7)  
MRD, N (%)    
 Negative (<0.01% positive cells) 
39 ( 35.5) 2 (  8.7) <0.001
Ψ
 
 
Positive   (≥0.01% positive cells) 53 ( 48.2) 8 ( 34.8)  
 Indeterminate 18 ( 16.4) 13 ( 56.5)  
  No targets 1 8  
  Targets not sensitive enough 9 2  
  
Not evaluable
θ 
6 2  
  
Other
Ω 
2 1  
Molecular Characteristics    
NOTCH1/FBXW7, N (%)    
 Wild type 33 (30.0) 14 (60.9) 0.011 
 Single Mutant 43 (39.1) 7 (30.4)  
 Double Mutant 34 (30.9) 2 (8.7)  
PTEN, N (%)    
 Wild type 77 (74.8) 17 (81.0) 0.55 
 Mutant 26 (25.2) 4 (19.1)  
RAS, N (%)    
 Wild type 100 (90.9) 20 (87.0) 0.70
*
 
 Mutant 10 (9.1) 3 (13.0)  
P values derived using Chi-squared tests unless otherwise indicated. 
*
Fisher’s exact test. 
#
Patients 
without bone marrow results at day 8 or 15 (assumed to be RER for treatment escalation) and one 
patient with conflicting slow early response data and bone marrow results. 
§
Excluding the unknown 
group: P = 0.26. 
Ψ
Excluding the indeterminate group: P = 0.31
*
.
 
θ
 Induction death (n=1), Inadequate 
diagnostic day 29 sample (n=7). 
Ω
Not analysed (n=1), reason missing (n=2). WBC, white blood cell 
count; NCI, National Cancer Institute; CNS, central nervous system; MRD, minimal residual disease.  
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Figure Legends 
 
Figure 1. qPCR and SNP array analysis at the TRG locus. (A) ABD status by 
qPCR TRG:ANLN fold change of WGA diagnostic samples from 149 patients. Three 
patients with an indeterminate (IND) result are not shown as their blast counts were 
<50%. (B) Representative Log-R ratio plot at the TRG locus (GRCh37/hg19 
chr7:37868112-38678273) from CytoSNP-850K arrays for an ABD and (C) a non-
ABD patient. Location of the V-J region amplified in the qPCR assay is shown.   
 
Figure 2. Outcome and MRD-positivity in patients grouped according to their 
ABD status. Kaplan-Meier curves for (A) OS and (B) RFS (C) EFS (D) Scatter-plot 
showing percentage of MRD-positive cells at day 29. Patients with ≥0.01% positive 
cells were classified as MRD-positive. Red line: median level. 
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SUPPLEMENTARY	INFORMATION	
Patient	cohort	Diagnostic	samples	from	previously	untreated	T-ALL	patients	enrolled	on	the	MRC	UKALL2003	 trial	were	analyzed.	The	 trial,	 registered	at	http://www.controlled-trials.com	 under	 the	 ISRCTN	 number	 07355119,	 opened	 in	 October	 2003	 for	patients	 aged	 1-18	 years.	 The	 upper	 age	 limit	 of	 the	 trial	 was	 increased	 in	September	2006	to	20	years	and	in	June	2008	to	25	years	of	age.	Samples	obtained	at	diagnosis	 from	152	of	 the	393	 (39%)	patients	with	T-ALL	were	available	 for	analysis.	Ethical	approval	for	the	trial	was	obtained	previously	from	the	Scottish	Multi-Centre	 Research	 Ethics	 Committee,	 and	 samples	 were	 collected	 with	informed	consent	according	to	the	Declaration	of	Helsinki.		
Details	of	the	trial	protocol	are	as	published1	and	are	outlined	in	Supplementary	Figure	S4-5.	At	trial	entry,	patients	with	National	Cancer	Institute	(NCI)	standard	risk	(<10	years	of	age	and	white	cell	count	[WCC]	<50x109/L)	were	assigned	to	regimen	 A	 while	 NCI	 high	 risk	 patients	 (≥10	 years	 and/or	 WCC	 ≥50x109/L)	received	regimen	B.	Patients	<16	years	with	a	slow	early	response	(≥25%	blasts	in	the	day	15	or	8	bone	marrow	for	regimens	A	or	B	respectively)	and	all	patients	with	high	 risk	 cytogenetics	 (KMT2A	 [MLL]	 and	TCF3-HLF	 fusions,	 near	 haploidy,	 low	hypodiploidy,	 and	 iAMP21)	were	assigned	 to	regimen	C.	MRD	was	evaluated	by	real-time	quantitative	PCR	 analysis	of	 immunoglobulin	and	T-cell	 receptor	gene	rearrangements	with	a	quantitative	 range	of	0·01%	as	defined	by	 the	European	MRD	Study	Group.2	Patients	with	undetectable	MRD	at	the	end	of	induction	(EOI,	day	29)	and	before	interim	maintenance	were	classified	as	MRD	low	risk,	as	were	
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those	who	had	detectable	EOI	MRD	(<0·01%)	but	undetectable	MRD	before	 the	start	of	 interim	maintenance.	MRD	 low	risk	patients	were	eligible	 for	 treatment	reduction	randomization.	Patients	with	EOI	MRD	≥0·01%	were	classified	as	MRD	high	risk	and	were	eligible	for	treatment	intensification	randomization	(Figure	S4).		
Materials	and	Methods	
Samples	
Whole-Genome-Amplified	(WGA)	diagnostic	genomic	DNA	(gDNA)	from	patient	samples	was	as	previously	prepared.3		
qPCR	assay	
The	quantitative	polymerase	chain	reaction	(qPCR)	assay	was	as	previously	described,4	and	evaluated	the	presence	or	absence	of	an	amplicon	within	the	intron	between	the	V	and	J	regions	of	the	TRG	locus	at	chromosome	7p14.	The	primers	(Forward:	5’-CATCCTCACTTTCCTGCTTCTTC-3’;	Reverse:	5’-CCAAGGTGAATCCCTACATGCT-3’)	amplified	an	87	base	pair	(bp)	amplicon	5089	bp	from	the	3’	end	of	the	TRGV11	pseudoexon	and	10123	bp	away	from	the	5’	end	of	TRGJP1	exon.	The	reference	gene	ANLN	lies	1.9Mb	downstream	of	TRG	at	7p15-14,	and	the	primers	(Forward:	5’-AAATTCTGCCCTTTGCTTGTTT-3’;	Reverse:	5’-GAAAGCAACCACAGAGAATATGTAAGTAA-3’)	amplified	an	89	bp	product.			
25µl	 PCR	 reactions	 were	 set	 up	 as	 follows:	 0.5µl	 of	 each	 forward	 and	 reverse	primer	(either	TRG	or	ANLN)	was	added	at	0.2µM,	12.5µl	2x	concentrated	ready-to-use	FastStart	Universal	SYBR	Green	Master	reaction	mix	(ROX)	(Roche,	2008),	2µl	genomic	DNA	template,	and	9.5µl	nuclease-free	water.	Samples	were	analyzed	
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in	 triplicate	 for	 each	 primer	 pair.	 The	 reactions	 were	 run	 on	 a	 Mastercycler	epgradient	S	thermocycler	(Eppendorf)	at	950C	for	10mins,	followed	by	40	cycles	of	950C	for	15	seconds	and	600C	for	1	min	for	each	cycle.	CT	(cycling	time)	values	were	obtained	from	the	Mastercycler	ep	Realplex	software.		
Standard	curves	using	dilutions	of	gDNA	from	the	non-leukemic	cell	line	HEK293T	that	does	not	have	a	rearrangement	of	the	TRG	locus	showed	that	the	primer	pair	efficiencies	were	very	similar	to	each	other	(E=1.84	and	1.817	for	TRG	and	ANLN	respectively).	The	ANLN	primer	pair	efficiencies	were	also	validated	using	gDNA	from	 Jurkat	 cells,	 a	 non-early	 T	 cell	 precursor	 cell	 line	 that	 does	 have	 a	rearrangement	of	the	TRG	gene.	
Mean	and	standard	deviation	(SD)	between	the	CT	values	of	each	sample	for	each	primer	pair	were	calculated.	If	the	SD	between	CT	values	of	the	replicates	for	the	PCR	 reaction	 of	 the	 reference	 gene,	 ANLN,	 was	 >0.5,	 then	 the	 reactions	 were	discarded	and	all	the	reactions	for	that	patient	sample	were	repeated.		
TRG:ANLN	fold	change	was	calculated	according	to	the	comparative	∆∆CT	method	using	 HEK293T	 gDNA	 as	 the	 calibrator.	 Each	 run	 included	 the	 positive	 control	(HEK293T	 gDNA)	 and	 a	 negative	 control	 (nuclease-free	water)	 for	 each	 primer	pair.	The	SD	of	the	HEK293T	CT	values	for	each	of	the	primer	pairs	showed	minimal	variability	across	the	runs	(n=14;	TRG:	mean	CT	value	23.7,	range	23.4-23.9,	SD	0.1;	
ANLN:	mean	CT	value	23.8,	range	23.6-23.9,	SD	0.1).	Therefore,	the	CT	results	of	the	 HEK293T	 sample	 of	 each	 run	was	 used	 as	 the	 calibrator	 value	 for	 the	 fold	change	calculations	for	samples	on	that	run.		
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Comparison	of	WGA	and	non-WGA	gDNA	fold	change		
TRG:ANLN	fold	change	calculated	by	the	method	above	using	WGA	gDNA	samples	was	validated	using	the	same	assay	in	the	corresponding	non-WGA	gDNA	samples	available	from	26	patients,	which	included	patients	with	fold	changes	that	covered	the	 entire	 range	 (mean	 fold	 change	 0.01–0.94).	 There	 was	 good	 agreement	between	the	fold	change	results	from	the	2	types	of	samples	(r2=0.92;	Figure	S2A),	with	a	bias	of	-0.023	and	an	agreement	interval	from	-0.201	to	0.155,	in	which	95%	of	the	differences	between	the	2	fold	changes	should	lie	(Figure	S2B).	One	patient	with	ABD	and	three	patients	with	non-ABD	in	the	WGA	samples	were	found	to	be	indeterminate	by	qPCR	assay	 in	 the	corresponding	non-WGA	samples.	However,	none	of	the	patients	had	their	ABD	status	change	from	ABD	to	non-ABD,	and	vice-versa,	when	comparing	the	WGA	and	the	corresponding	non-WGA	results.		
Validation	of	fold	change	using	a	different	reference	gene	
The	 fold	 change	 results	 that	 were	 indeterminate	 by	 the	 qPCR	 assay	 above	(TRG:ANLN	fold	change	0.26-0.49)	were	validated	using	a	different	reference	gene	encoding	 the	 mitochondrial	 protein	 Cytochrome	 c	 Oxidase	 Assembly	 factor	 1	(COA1),	which	lies	4MB	upstream	of	the	TRG	locus,	to	abrogate	the	possibility	that	abnormalities	 of	 the	 ANLN	 reference	 gene	 itself	 may	 have	 contributed	 to	 the	indeterminate	 fold	 change	 calculation.	 The	 COA1	 primers	 (Forward:	 5’-GGAAAACTGGGTTGCAGGAG-3’;	 Reverse:	 5’-AGAAGACCCAGCTTGCTTCT-3’)	amplified	a	105bp	product.	
TRG	and	COA1	assays	were	performed	in	triplicate	using	the	same	PCR	reaction	reagents,	 calibrator	 and	 conditions	 as	 described	 above	 and	 the	 TRG:COA1	 fold	
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change	calculated.	Standard	curves	using	dilutions	of	gDNA	from	HEK293T	cells	were	set	up	using	the	COA1	primers	and	the	efficiency	was	comparable	to	that	of	the	TRG	primers	(E=1.96	and	E=1.84	for	COA1	and	TRG	respectively).	
The	TRG:COA1	fold	change	led	to	the	same	ABD	status	assignment	as	that	of	the	TRG:ANLN	fold	change	for	7	patients	that	had	informative	TRG:ANLN	fold	change	results	(data	not	shown).	The	TRG:COA1	fold	change	results	for	15	patients	with	indeterminate	TRG:ANLN	did	not	change	the	ABD	assignment	 from	ABD	to	non-ABD	or	vice	versa,	although	3	patients	had	fold	changes	in	this	assay	that	varied	from	those	of	the	TRG:ANLN	assay	only	across	the	thresholds	of	0.26-0.49	of	the	indeterminate	 range	 (Figure	 S2C).	 As	 a	 result	 of	 the	 inconclusive	 fold	 change	results	 from	both	 the	TRG:ANLN	and	TRG:COA1	assays	 for	 these	 samples,	 these	patients	were	assigned	the	ABD	indeterminate	status.	
SNP	array	analysis	
WGA	gDNA	samples	were	previously	analyzed	using	the	Infinium	CytoSNP-850K	Beadchip	array	(Illumina,	Essex,	UK).3	Log-R	intensities	and	B-allele	frequencies	for	each	 of	 the	 62	 SNP	markers	 across	 the	 region	 hg19	 chr7:38288270-38385938	which	includes	the	TRG	 locus	were	assessed	 independently	by	4	 individuals	and	the	TRG	locus	deletion	status	was	scored	as	no	or	heterozygous	deletion	(ABD),	or	homozygous	deletion	(non-ABD).		
Statistical	Analysis	
Survival	curves	were	plotted	using	Kaplan-Meier	analysis	for	overall	survival	(time	from	 the	 start	 of	 treatment	 until	 death),	 event-free	 survival	 (time	 to	 relapse,	
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secondary	tumor	or	death,	whichever	came	first)	and	relapse-free	survival	(time	to	relapse	 in	 those	who	achieved	 remission).	Patients	who	died	 in	 remission	were	censored.	Those	who	did	not	have	an	event	were	censored	at	 the	date	 last	seen.	Comparisons	between	groups	were	carried	out	using	Cox	regression	and	the	log	rank	test.	Differences	between	the	median	Day	29	MRD	results	in	the	ABD	and	non-ABD	 groups	 was	 compared	 using	 the	 Wilcoxon	 Mann-Whitney	 test.	 Statistical	analysis	 was	 conducted	 using	 STATA	 version	 14.2	 (STATACORP,	 Texas),	 MRD	scatter	plot	drawn	using	GraphPad	Prism	6	(GraphPad	Software,	Inc,	California).		
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Supplementary	Tables	
	
Table	S1:		Comparison	of	the	baseline	characteristics,	treatment	allocation	
and	response	of	T-ALL	patients	that	were	(n=152)	or	were	not	(n=241)	
included	in	the	study.		
	
 Patients with samples 
Patients without 
samples P 
N=152 N=241 
Baseline characteristics    
Sex, N (%)    
 Male 117 ( 77.0) 168 ( 69.7) 0.12 
 Female 35 ( 23.0) 73 ( 30.3)  
WBC count (x109/L), N (%)    
 <50 48 ( 31.6) 95 ( 39.4) 0.12 
 ≥50 104 ( 68.4) 146 ( 60.6)  
Age, N (%)    
 <10 years 82 ( 53.9) 107 ( 44.4) 0.07 
 ≥10 years 70 ( 46.1) 134 ( 55.6)  
NCI risk group, N (%)    
 Standard 19 ( 12.5) 40 ( 16.6) 0.27 
 High 133 ( 87.5) 201 ( 83.4)  
CNS disease at diagnosis, N (%)    
 No 144 ( 94.7) 225 ( 93.4) 0.58 
 Yes 8 (  5.3) 16 (  6.6)  
Final Treatment Allocation and 
Response  
  
Final treatment given, N (%)    
 A 14 (  9.2) 30 ( 12.4) 0.25 
 B 87 ( 57.2) 118 ( 49.0)  
 C 51 ( 33.6) 93 ( 38.6)  
Slow early Response, N (%)    
 No 97 ( 63.8) 148 ( 61.4) 0.55# 
 Yes 37 ( 24.3) 55 ( 22.8)  
 Unknown* 18 ( 11.8) 38 ( 15.8)  
MRD, N (%)    
 Negative (<0.01% positive cells) 50 ( 32.9) 70 ( 29.0) 0.25§ 
 Positive   (³0.01% positive cells) 67 ( 44.1) 97 ( 40.2)  
 IndeterminateY 35 ( 23.0) 74 ( 30.7)  
   
P	values	derived	using	Chi-squared	tests.	*Patients	without	bone	marrow	results	at	day	8	or	15	(assumed	to	have	rapid	early	response	for	treatment	escalation	decision)	and	two	patients	with	conflicting	slow	early	response	data	and	bone	marrow	results.	#Excluding	the	unknown	group:	P	=	0.92.	§Excluding	the	indeterminate	group:	P	=	0.89.	YIncludes	samples	where	there	were	either	no	targets	for	MRD	assessment	or	the	targets	were	not	sensitive	enough,	and	samples	where	MRD	was	either	not	analysed	or	was	unevaluable	due	to	the	sample	being	inadequate	or	having	missing	data.	WBC,	white	blood	cell	count;	NCI,	National	Cancer	Institute,	CNS,	central	nervous	system;	MRD,	minimal	residual	disease.		
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Table	S2:		Time-to-event	outcomes	comparing	the	groups	with	and	without	
samples	for	ABD	analysis.		
 
 
  Events/n HR (95% CI) P 5-year rate (95% CI) 
      
EFS      
 Without samples 59/241 1.00 0.075 76.9% (71.0 – 81.8) 
 With samples 27/152 0.66 (0.42 – 1.05)  84.2% (77.4 – 89.1) 
RFS      
 Without samples 37/239 1.00 0.41 84.9% (79.4 – 89.0) 
 With samples 20/151 0.80 (0.46 – 1.38)  87.2% (80.7 – 91.6) 
OS      
 Without samples 43/241 1.00 0.074 82.8% (77.4 – 87.0) 
 With samples 18/152 0.61 (0.35 – 1.05)  89.5% (83.4 – 93.4) 
 
P	values	calculated	using	the	log	rank	test.	EFS,	Event-Free	Survival;	RFS,	Relapse-Free	Survival;	OS,	Overall	Survival;	HR,	Hazard	Ratio;	CI,	Confidence	Interval.			 	
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Table	S3.	Comparison	of	baseline	characteristics,	treatment	allocation,	
response	and	molecular	characterisation	of	patients	with	definitive	and	
indeterminate	qPCR	results	for	the	ABD	assay.		
 qPCR result Indeterminate qPCR result P N=133 N=19 
Baseline characteristics    
Sex, N (%)    
 Male 104 ( 78.2) 13 ( 68.4) 0.38* 
 Female 29 ( 21.8) 6 ( 31.6)  
WBC count (x109 per L), N (%)    
 <50 39 ( 29.3) 9 ( 47.4) 0.11 
 ≥50 94 ( 70.7) 10 ( 52.6)  
Age, N (%)    
 <10 years 72 ( 54.1) 10 ( 52.6) 0.90 
 ≥10 years 61 ( 45.9) 9 ( 47.4)  
NCI risk group, N (%)    
 Standard 14 ( 10.5) 5 ( 26.3) 0.066* 
 High 119 ( 89.5) 14 ( 73.7)  
CNS disease at diagnosis, N (%)    
 No 125 ( 94.0) 19 (100.0) 0.60* 
 Yes 8 (  6.0) 0  
Final Treatment Allocation and 
Response    
Final treatment given, N (%)    
 A 11 (  8.3) 3 ( 15.8) 0.53* 
 B 76 ( 57.1) 11 ( 57.9)  
 C 46 ( 34.6) 5 ( 26.3)  
Slow early Response, N (%)    
 No 85 ( 63.9) 12 ( 63.2) >0.99*,§ 
 Yes 32 ( 24.1) 5 ( 26.3)  
 Unknown# 16 ( 12.0) 2 ( 10.5)  
MRD, N (%)    
 Negative (<0.01% positive cells) 41 ( 30.8) 9 ( 47.4) 0.34*,Y 
 Positive   (³0.01% positive cells) 61 ( 45.9) 6 ( 31.6)  
 Indeterminateq 31 ( 23.3) 4 ( 21.1)  
Molecular Characterisation    
NOTCH1/FBXW7, N (%)    
 Wild type 47 (35.3) 6 (31.6) 0.20* 
 Single Mutant 50 (37.6) 11 (57.9)  
 Double Mutant 36 (27.1) 2 (10.5)  
PTEN, N (%)    
 Wild type 94 (75.8) 17 (94.4) 0.12* 
 Mutant 30 (24.2) 1 (5.6)  
RAS, N (%)    
 Wild type 120 (90.2) 17 (89.5) >0.99 
 Mutant 13 (9.8) 2 (10.5)  
P	values	derived	using	Chi-squared	tests	unless	otherwise	indicated.	*Fisher’s	exact	test.	#Patients	without	bone	marrow	results	at	day	8	or	15	(assumed	to	be	RER	for	treatment	escalation)	and	one	patient	with	conflicting	slow	early	response	data	and	bone	marrow	results.	§Excluding	the	unknown	group:	P	>0.99.	YExcluding	the	indeterminate	group:	P	=	0.15.	
qIncludes	samples	where	there	were	either	no	targets	for	MRD	assessment	or	the	targets	were	not	sensitive	enough,	and	samples	where	MRD	was	either	not	analysed	or	was	unevaluable	due	to	the	sample	being	inadequate	or	having	missing	data.	WBC,	white	blood	cell	count;	NCI,	National	Cancer	Institute,	CNS,	central	nervous	system;	MRD,	minimal	residual	disease.		 	
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Table	S4:	Time-to-event	outcomes	comparing	the	groups	with	definitive	and	
indeterminate	qPCR	results	for	the	ABD	assay.		
 
  Events/n HR (95% CI) P 5-year rate (95% CI) 
      
EFS      
 qPCR result 24/133 1.00 0.81 84.2% (76.8 – 89.4) 
 Indeterminate qPCR 3/19 0.86 (0.26 – 2.87)  84.2% (58.7 – 94.6) 
RFS      
 qPCR result 17/132 1.00 0.75 87.6% (80.6 – 92.2) 
 Indeterminate qPCR 3/19 1.22 (0.36 – 4.17)  84.2% (58.7 – 94.6) 
OS      
 qPCR result 16/133 1.00 0.83 89.5% (82.9 – 93.6) 
 Indeterminate qPCR 2/19 0.85 (0.20 – 3.71)  89.5% (64.1 – 97.3) 
 
P	values	calculated	using	the	log	rank	test. EFS,	Event-Free	Survival;	RFS,	Relapse-Free	Survival;	OS,	Overall	Survival;	HR,	Hazard	Ratio;	CI,	Confidence	Interval. 
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Table	S5:	Time-to-event	outcomes	comparing	the	ABD	and	non-ABD	groups.		
 
  Events/n HR (95% CI) P 5-year rate (95% CI) 
      
EFS      
 Non-ABD 17/110 1.00 0.09 85.4% (79.5 – 92.3) 
 ABD 7/23 2.12 (0.88 – 5.12)  77.3% (55.4 – 90.3) 
RFS      
 Non-ABD 13/110 1.00 0.42 88.8% (81.1 – 93.5) 
 ABD 4/22 1.58 (0.52 – 4.86)  81.8% (58.5 – 92.8) 
OS      
 Non-ABD 12/110 1.00 0.37 90.0% (82.7 – 94.3) 
 ABD 4/23 1.67 (0.54 – 5.17)  87.0% (64.8 – 95.6) 
 
 
P	values	calculated	using	the	log	rank	test.	EFS,	Event-Free	Survival;	RFS,	Relapse-Free	Survival;	OS,	Overall	Survival;	HR,	Hazard	Ratio;	CI,	Confidence	Interval.	
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Table	S6:	Relapse-free	survival	comparing	the	ABD	and	non-ABD	groups	
treated	on	Regimens	A/B	and	C.	
 
 Events/n HR (95% CI) P 5-year rate (95% CI) 
Regimen A/B     
Non-ABD 7/75 1.00 0.31 91.9% (82.8 – 96.3) 
ABD 0/11 -   100% 
Regimen C      
Non-ABD 6/35 1.00 0.21 82.1% (64.4 – 91.6) 
ABD 4/11 2.19 (0.62 – 7.78)  63.6% (29.7 – 84.5) 
 
P	values	calculated	using	the	log	rank	test.	HR,	Hazard	Ratio;	CI,	Confidence	Interval.		
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Supplementary	Figure	Legends	
Figure	 S1.	 Kaplan-Meier	 survival	 curves	 of	 the	 patients	 included	 or	 not	
included	in	the	study.	(A)	Overall	Survival,	(B)	Event-Free	Survival,	(C)	Relapse-Free	Survival.	
	
Figure	S2.	Validation	of	the	TRG:ANLN	qPCR	assay.	(A)	Comparison	of	results	obtained	 using	 WGA	 and	 Non-WGA	 samples	 from	 26	 patients	 with	 available	material.	 (B)	Bland-Altman	plot	showing	the	differences	between	the	TRG:ANLN	WGA	and	non-WGA	results	plotted	against	the	mean	of	each	pair	of	fold	changes.	The	shaded	area	shows	the	agreement	interval	in	which	95%	of	the	differences	are	expected	 to	 lie.	 (C)	 TRG:ANLN	 and	 TRG:COA1	 fold	 changes	 for	 diagnostic	WGA	samples	 from	 15	 patients	 with	 indeterminate	 ABD	 status	 by	 TRG:ANLN	 fold	change.			
Figure	S3.	Kaplan-Meier	survival	curves	of	the	patients	with	definitive	and	
indeterminate	qPCR	 results.	 (A)	Overall	 Survival,	 (B)	 Event-Free	 Survival,	 (C)	Relapse-Free	Survival.		
Figure	S4.	Schematic	diagram	of	the	UKALL2003	trial	protocol.	(A)	Treatment	intensity	 decision	 points,	 (B)	 Randomization	 arms	 of	 the	 trial	 based	 on	 MRD	analysis.	Slow	Early	Response	defined	as	≥25%	blasts	in	the	Day	15	bone	marrow	for	Regimen	A	and	Day	8	marrow	for	Regimen	B;	High	Risk	Cytogenetics	includes	
KMT2A	[MLL]	and	TCF3-HLF	fusions,	near	haploidy,	low	hypodiploidy,	and	iAMP21;	MRD	 positive	 defined	 as	 ³0.01%	 positive	 cells	 and	 MRD	 negative	 as	 <0.01%	positive	 cells;	 MRD	 indeterminate	 includes	 samples	 with	 no	 targets	 for	 MRD	
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assessment	or	targets	were	present	but	not	sensitive	enough,	and	samples	where	MRD	 was	 either	 not	 analysed	 or	 was	 not	 evaluable	 due	 to	 the	 sample	 being	inadequate	 or	 having	 missing	 data.	 Abbreviations:	 ALL,	 Acute	 Lymphoblastic	Leukemia;	MRD,	Minimal	Residual	Disease;	WCC,	White	Cell	Count.		
Figure	S5.	Schematic	diagram	of	the	UKALL2003	treatment	regimens	A,	B	and	
C.	 Regimen	 A:	 3	 drug	 induction	 with	 vincristine,	 dexamethasone,	 asparaginase	followed	by	consolidation	with	daily	mercaptopurine	and	central	nervous	system	(CNS)-directed	 therapy	 with	 weekly	 intrathecal	 methotrexate.	 Interim	Maintenance	 (IM):	 daily	 mercaptopurine,	 weekly	 methotrexate,	 monthly	vincristine	and	corticosteroid	pulses;	Delayed	 Intensification	 (DI):	 asparaginase,	vincristine,	 dexamethasone,	 doxorubicin,	 cyclophosphamide	 and	 cytarabine;	Continuing	Therapy:	oral	mercaptopurine	and	methotrexate,	monthly	vincristine,		corticosteroid	pulses,	and	intrathecal	methotrexate	every	3	months.		Regimen	B:	4	drug	 induction:	 daunorubicin	 in	 addition	 to	 dugs	 used	 in	 regimen	 A	 induction.	Consolidation	phase	as	 in	Regimen	A	with	the	addition	of	BFM,	Berlin	Frankfurt	Munster	(4	weeks	of	cyclophosphamide	and	cytarabine).		Regimen	C:	Augmented	consolidation	 by	 addition	 of	 4	 doses	 of	 vincristine	 and	 2	 doses	 of	 pegylated	asparaginase	 during	 BFM	 consolidation.	 Capizzi	 maintenance	 as	 interim	maintenance	 consisted	 of	 escalating	doses	of	 intravenous	methotrexate	without	folinic	 acid	 rescue,	 and	 vincristine	 and	 pegylated	 asparaginase.	 Abbreviations:	MRD,	 minimal	 residual	 disease;	 CNS,	 central	 nervous	 system;	 	 IM,	 interim	maintenance;	DI,	delayed	intensification;	BFM,	Berlin	Frankfurt	Munster.		Further	treatment	regimen	details	available	at	Vora	et	al5	and	O’Connor	et	al.6	
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Figure	S6.	Kaplan-Meier	survival	curves	grouped	according	to	ABD	status	for	
patients	on	different	treatment	regimens.	Relapse-Free	Survival	for	patients	on	(A)	Regimen	C,	(B)	Regimen	A	or	B,	and	(C)	those	with	positive	MRD	regardless	of	treatment	regimen.		
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